Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Signs further Memorandum of Understanding with International Co-Innovation Centre for Advanced Medical Technology for a clinical pilot study with the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. The clinical pilot study will evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer.
In February, Cizzle signed a full agreement for development of lung cancer tests in China with the International Co-Innovation Centre for Advanced Medical Technology and the Shenzhen Intelliphecy Life Technologies Co Ltd.
Chair Allan Syms: ‘We are delighted to announce this further MoU focused on our clinical trial programme at CMEF which is the largest HealthTech expo in China, attracting over 100,000 attendees each year, and bringing together leading international medical equipment companies, doctors, regulators and government agencies.’
Current stock price: 1.66 pence
12-month change: down 59%
Copyright 2022 Alliance News Limited. All Rights Reserved.
